drugset / Trial / NCT05262751
A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this trial is to assess single dose drug exposure of several newly developed formulation prototypes of Nintedanib compared to Ofev® following oral administration.
Timeline
- Start
- 2022-03-28
- Primary completion
- 2022-11-30
- Completion
- 2022-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nintedanib | Small molecule | — | Oral |
| Subject | Ofev® | Unknown | — | Oral |
Indications
No indication recorded.